Search Results | Blood | American Society of Hematology

1-20 of 1682

2 3 4 5

Sort by

Sort Order Select

Journal Articles

Relapse risk following truncation of pegylated asparaginase in childhood acute lymphoblastic leukemia

Sofie Gottschalk Højfeldt, Kathrine Grell, Jonas Abrahamsson, Bendik Lund, Kim Vettenranta, Ólafur G. Jónsson, Thomas L. Frandsen, Benjamin O. Wolthers, Hanne Vibeke Marquart, Goda Vaitkeviciene, Kristi Lepik, Mats Heyman, Kjeld Schmiegelow, Birgitte Klug Albertsen

Blood (2021) 137 (17): 2373–2382.

DOI: https://doi.org/10.1182/blood.2020006583

Published: 2021

Includes: Supplemental data

Journal Articles

Integrated omics approaches to predict T-LBL relapse risk

Guillaume P. Andrieu, Vahid Asnafi

Blood (2021) 137 (17): 2280–2282.

DOI: https://doi.org/10.1182/blood.2020009599

Published: 2021

Journal Articles

How I treat warm autoimmune hemolytic anemia

Wilma Barcellini, Bruno Fattizzo

Blood (2021) 137 (10): 1283–1294.

DOI: https://doi.org/10.1182/blood.2019003808

Published: 2021

Journal Articles

Effects of germline DHFR and FPGS variants on methotrexate metabolism and relapse of leukemia

Blood (2020) 136 (10): 1161–1168.

DOI: https://doi.org/10.1182/blood.2020005064

Published: 2020

Includes: Supplemental data

Journal Articles

A validated novel continuous prognostic index to deliver stratified medicine in pediatric acute lymphoblastic leukemia

Blood (2020) 135 (17): 1438–1446.

DOI: https://doi.org/10.1182/blood.2019003191

Published: 2020

Includes: Supplemental data

Journal Articles

Reduced–dose intensity therapy for pediatric lymphoblastic leukemia: long-term results of the Recife RELLA05 pilot study

Francisco Pedrosa, Elaine Coustan-Smith, Yinmei Zhou, Cheng Cheng, Arli Pedrosa, Mecneide Mendes Lins, Marcia Pedrosa, Norma Lucena-Silva, Alessandra Maria de Luna Ramos, Ester Vinhas, Gaston K. Rivera, Dario Campana, Raul C. Ribeiro

Blood (2020) 135 (17): 1458–1466.

DOI: https://doi.org/10.1182/blood.2019004215

Published: 2020

Includes: Supplemental data

Journal Articles

Managing thromboembolic risk in patients with hereditary and acquired thrombophilias

Jason Moran, Kenneth A. Bauer

Blood (2020) 135 (5): 344–350.

DOI: https://doi.org/10.1182/blood.2019000917

Published: 2020

Journal Articles

Cognitive Impairment Is Associated with Inferior Survival and Increased Non-Relapse Mortality in Older Allogeneic Hematopoietic Cell Transplant (alloHCT) Recipients: A Multicenter Retrospective Study

Rebecca L. Olin, MD, Caitrin Fretham, Marcelo C. Pasquini, MD, Mukta Arora, MD, Vijaya R. Bhatt, MD, Benjamin Derman, MDBA, Sergio A Giralt, MD, Li-Wen Huang, MD, Thuy T. Koll, MD, Sang Mee Lee, PhD, Richard J Lin, MD PhD, Linda Pang, MD, Uday Popat, MD, Daniel J. Weisdorf, MD, Andrew S. Artz, MD

Blood (2019) 134 (Supplement_1): 4606.

DOI: https://doi.org/10.1182/blood-2019-123598

Published: 2019

Journal Articles

High Risk of Relapse with Intermediate Dose Cytarabine for Consolidation in Young Favorable Risk AML Patients Following Induction with 7+3

Bhaskar Kolla, MBBS, Nurul Aidah Abdul Halim, MBBS, Zohar Sachs, MD PhD, Erica D. Warlick, MD, Daniel J. Weisdorf, MD, Fiona He, MD, Lao Zhentang, MBBS, MRCP

Blood (2019) 134 (Supplement_1): 3432.

DOI: https://doi.org/10.1182/blood-2019-123306

Published: 2019

Journal Articles

Cancer-Related Distress and Unmet Needs Among Acute Myeloid Leukemia Survivors

Alexandra K Zaleta, PhD, Pierre Gardan, Shauna McManus, BS, Melissa F. Miller, PhD MPH, Kelly Clark, MA, Nicole E Nicksic, PhD MPH, Hildy Dillon, MPH, Tara Albrecht, PhDANP, Areej El-Jawahri, MD, Clare Karten, MS, Thomas W. LeBlanc, MDMA,MHS, Jane L. Liesveld, MD, Elizabeth Muenks, PhD, Barbara B. Rogers, CRNP, MN, AOCN, ANP-BC, Kristin Scheeler, MS, Linda House, RN, BSN, MSM

Blood (2019) 134 (Supplement_1): 4787.

DOI: https://doi.org/10.1182/blood-2019-123456

Published: 2019

Journal Articles

Outcomes Following Allogeneic Stem Cell Transplantation for AML in First Completion Remission Are Comparable between MRD Negative Patients and MRD Positive Patients Receiving Induction Only and Are Superior to MRD Positive Patients Receiving Induction and Additional Therapy

Jonathan A Gutman, MD, Prashant Sharma, MD, Enkhtsetseg Purev, MD, Clayton Smith, MD, Amanda Winters, MD PhD, Andrew Hammes, MS, Michael R. Loken, PhD, Daniel A Pollyea, MD

Blood (2019) 134 (Supplement_1): 4615.

DOI: https://doi.org/10.1182/blood-2019-129150

Published: 2019

Journal Articles

Clearance of Somatic Gene Mutations in Patients with Acute Myeloid Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Predicts Outcome

Blood (2019) 134 (Supplement_1): 4621.

DOI: https://doi.org/10.1182/blood-2019-130922

Published: 2019

Journal Articles

Validation of the Revised AML-Composite Model for the Prediction of Prognosis in Older Patients Receiving Intensive Induction Therapy

Corentin Orvain, Aline Tanguy-Schmidt, Sylvain Thepot, MD, Anne Bouvier, Benedicte Ribourtout, Franck Genevieve, Aurelien Giltat, Marion Champire, Adeline Chanson, Marielle Subileau, Damien Luque Paz, Valerie Ugo, Norbert Ifrah, Mathilde Hunault, MD PhD

Blood (2019) 134 (Supplement_1): 1310.

DOI: https://doi.org/10.1182/blood-2019-127351

Published: 2019

Journal Articles

A Phase 2 Study of Glasdegib for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with High Risk of Post-Allogeneic Stem Cell Transplantation Relapse

Andrew Kent, MD PhD, Sumithira Vasu, MDMBBS, Derek Schatz, Natalie Monson, Steven Devine, MD, Clayton Smith, MD, Jonathan A Gutman, MD, Daniel A Pollyea, MD

Blood (2019) 134 (Supplement_1): 1311.

DOI: https://doi.org/10.1182/blood-2019-127418

Published: 2019

Journal Articles

A Novel Combination Regimen of BET and FLT3 Inhibition for FLT3-ITD Acute Myeloid Leukemia

Lauren Lee, Yoshiyuki Hizukuri, Paul Severson, Ben Powell, PhD, Chao Zhang, PhD, Yan Ma, Maiko Narahara, Hiroyuki Sumi, PhD, Gideon Bollag, PhD, Mark J. Levis, MD

Blood (2019) 134 (Supplement_1): 1373.

DOI: https://doi.org/10.1182/blood-2019-124030

Published: 2019

Journal Articles

French National Retrospective Cohort of Hairy-Cell Leukemias: Risk of Second Malignancies after 10 Years of Follow-up

Blood (2019) 134 (Supplement_1): 1537.

DOI: https://doi.org/10.1182/blood-2019-127560

Published: 2019

Journal Articles

A 9-Gene Expression Signature Identifies Patients with Core-Binding Factor Acute Myeloid Leukemia at High Risk of Relapse after Achieving Complete Remission

Guillaume Richard-Carpentier, MD, Miriam Marquis, PhD, Francois Beliveau, PhD, Guy Sauvageau, MD PhD, Josee Hebert, MD

Blood (2019) 134 (Supplement_1): 1432.

DOI: https://doi.org/10.1182/blood-2019-129990

Published: 2019

Journal Articles

Survival Analysis According to Minimal Residual Disease By Flow Cytometry in Acute Myeloid Leukemia after First Induction

Claudia Nunez-Torron, MD, Juan Marquet Palomanes, MD, Fernando Martín Moro, Adolfo Saez-Martin, MD, Alejandro Luna, MD, Irene Garcia-Garcia, Berta Mercedes Michael Fernández, Jesus Villarrubia, PhD, Miguel Piris-Villaespesa, MD, Ernesto Roldan Santiago, Eulalia Rodríguez Martín, Gemma Moreno, MD, Valentín García Gutiérrez, PhD, Javier Lopez Jimenez, MD PhD, Pilar Herrera Puente

Blood (2019) 134 (Supplement_1): 1433.

DOI: https://doi.org/10.1182/blood-2019-130190

Published: 2019

Journal Articles

NPM1 mutations Using Deep Amplicon Sequencing and Broad Next Generation Sequencing at the Time of Complete Remission Is Informative to Predicting Risk of Relapse Following Intensive Chemotherapy

Bhavana Bhatnagar, DO, Shelley Orwick, BS, Nyla A. Heerema, PhD, Alison R. Walker, MD, Alice S. Mims, MD, James S. Blachly, MD, Karilyn Larkin, MD, Nicole Grieselhuber, MD PhD, Gregory K. Behbehani, MD PhD, Apollinaire Ngankeu, Charles Thomas Gregory, BS, John C. Byrd, MD

Blood (2019) 134 (Supplement_1): 1329.

DOI: https://doi.org/10.1182/blood-2019-130856

Published: 2019

Journal Articles

Superior Outcome in Elderly AML Patients Receiving Adjuvant Serotonin-Reuptake-Inhibitors during Induction

Rafee Talukder, MD, Martha P. Mims, MD PhD, Gustavo A. Rivero, MD

Blood (2019) 134 (Supplement_1): 1438.

DOI: https://doi.org/10.1182/blood-2019-131581

Published: 2019

2 3 4 5

NARROW

Relapse risk following truncation of pegylated asparaginase in childhood acute lymphoblastic leukemia

Integrated omics approaches to predict T-LBL relapse risk

How I treat warm autoimmune hemolytic anemia

Effects of germline DHFR and FPGS variants on methotrexate metabolism and relapse of leukemia

A validated novel continuous prognostic index to deliver stratified medicine in pediatric acute lymphoblastic leukemia

Reduced–dose intensity therapy for pediatric lymphoblastic leukemia: long-term results of the Recife RELLA05 pilot study

Managing thromboembolic risk in patients with hereditary and acquired thrombophilias

Cognitive Impairment Is Associated with Inferior Survival and Increased Non-Relapse Mortality in Older Allogeneic Hematopoietic Cell Transplant (alloHCT) Recipients: A Multicenter Retrospective Study

High Risk of Relapse with Intermediate Dose Cytarabine for Consolidation in Young Favorable Risk AML Patients Following Induction with 7+3

Cancer-Related Distress and Unmet Needs Among Acute Myeloid Leukemia Survivors

Outcomes Following Allogeneic Stem Cell Transplantation for AML in First Completion Remission Are Comparable between MRD Negative Patients and MRD Positive Patients Receiving Induction Only and Are Superior to MRD Positive Patients Receiving Induction and Additional Therapy

Clearance of Somatic Gene Mutations in Patients with Acute Myeloid Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Predicts Outcome

Validation of the Revised AML-Composite Model for the Prediction of Prognosis in Older Patients Receiving Intensive Induction Therapy

A Phase 2 Study of Glasdegib for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with High Risk of Post-Allogeneic Stem Cell Transplantation Relapse

A Novel Combination Regimen of BET and FLT3 Inhibition for FLT3-ITD Acute Myeloid Leukemia

French National Retrospective Cohort of Hairy-Cell Leukemias: Risk of Second Malignancies after 10 Years of Follow-up

A 9-Gene Expression Signature Identifies Patients with Core-Binding Factor Acute Myeloid Leukemia at High Risk of Relapse after Achieving Complete Remission

Survival Analysis According to Minimal Residual Disease By Flow Cytometry in Acute Myeloid Leukemia after First Induction

NPM1 mutations Using Deep Amplicon Sequencing and Broad Next Generation Sequencing at the Time of Complete Remission Is Informative to Predicting Risk of Relapse Following Intensive Chemotherapy

Superior Outcome in Elderly AML Patients Receiving Adjuvant Serotonin-Reuptake-Inhibitors during Induction

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only